Private investment in biotechnology companies continues to churn out startups and support the next stage of drug development for established early-stage firms, despite the rollercoaster rise and fall of public biotech company valuations, with venture capital firms continuing to raise money for new funds and invest the proceeds in new opportunities.
Frazier Healthcare Partners in Menlo Park, California recently closed Frazier Life Sciences VIII LP with $262m to fund companies that are developing novel therapeutics – its first life science fund focused specifically on drug developers ranging from preclinical, early-stage startups to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
